T-Therapeutics Ltd
Chris Herring has extensive work experience in the pharmaceutical and biotechnology industry. Chris currently holds the position of VP, TCR-T at T-Therapeutics Ltd since May 2023. Prior to this, they worked at Adaptimmune as a Senior Director of Discovery Research from September 2020 to May 2023 and then as a VP of Discovery Research from July 2021 to April 2023. Chris also worked at GSK as a Director from August 2016 to September 2020 and as a Manager and Head of Protein Sciences from an unknown start date in 2007 to August 2016. Additionally, they served as a Manager and Head of Protein Sciences at Domantis/GSK from an unknown start date in 2009 to September 2020. Chris began their career as a Research Associate at the University of Cambridge from an unknown start date in 1996 to an unknown end date in 1998.
Chris Herring completed their education from the year 1988 to 1992 at the University of Surrey, where they earned a Bachelor of Science (Hons) degree in Biochemistry. Following this, from 1992 to 1996, they pursued their PhD at The University of Manchester, specializing in the field of DNA repair.
This person is not in any teams
T-Therapeutics Ltd
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.